美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Virtus LifeSci Biotech Products ETF

104.04

-0.8785-0.84%

成交量：6,293

成交額：65.50萬

市值：1.30億

市盈率：- -

高：104.53

開：104.53

低：103.99

收：104.92

52周最高：110.05

52周最低：68.05

股本：125.00萬

流通股本：125.00萬

量比：2.34

換手率：0.50%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

東方證券：AI重構創新藥研發底座國內相關產業鏈公司亦有望受益

新聞稿：Ernexa Therapeutics 引入資深生物技術高管 David Polinsky 加入董事會，為臨床階段衝刺蓄力

GLP-1為王、專利懸崖逼近、新賽道搶跑跨國藥企2026上半年業績背後的版圖重組

每日经济新闻

GLP-1為王、專利懸崖逼近、新賽道搶跑：跨國藥企2026上半年業績背後的版圖重組

每日经济新闻

阿斯利康擬與百時美施貴寶4000億美元重組傳聞背後：專利懸崖、產品短板倒逼，AZ端反對聲大

全球能源市場速覽：市場動態簡報

全球外匯與固定收益市場綜述：交易動態一覽

總部位於荷蘭阿姆斯特丹的全球生物製藥公司 ARGENX將以每股77美元的現金收購FORTE BIOSCIENCES。

全球外匯與固收市場動態：市場對話精選

安永：至2028年全球前25大醫藥企業存在千億美元增長缺口

創新藥研發加速遇「猴荒」

免疫疾病生物製藥公司Attovia(ATTO.US)申請在美上市擬募資1億美元

免疫疾病生物製藥公司Attovia(ATTO.US)申請在美上市擬募資1億美元

免疫疾病生物製藥公司Attovia(ATTO.US)申請在美上市擬募資1億美元

英硅智能早盤升逾7% 與康哲藥業達成AI+創新藥研發新合作

韓國上半年生物製藥出口額料達45億美元，創歷史同期新高

韓國上半年生物製藥出口額料達45億美元，創歷史同期新高

环球市场播报

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BBP/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Products ETF","latestPrice":104.04,"timestamp":1789742833505,"preClose":104.9185,"halted":0,"volume":6293,"delay":0,"changeRate":-0.008373165838245765,"floatShares":1250004,"shares":1250004,"eps":0,"marketStatus":"交易中","change":-0.8785,"latestTime":"09-18 10:54:15 EDT","open":104.525,"high":104.525,"low":103.985,"amount":655013.26093,"amplitude":0.005147,"askPrice":104.29,"askSize":100,"bidPrice":103.04,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789761600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":104.9185,"sharesOutstanding":600004,"nav":102.17,"aum":127713134.29,"bidAskSpread":0.002459,"preHourTrading":{"tag":"盘前","latestPrice":104.9185,"preClose":104.9185,"latestTime":"07:00 EDT","volume":1,"amount":104.9185,"timestamp":1789729242647,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":108.32,"preClose":104.9185,"latestTime":"19:30 EDT","volume":160,"amount":17307.3895,"timestamp":1789687804652,"change":3.4015,"changeRate":0.03242,"amplitude":0.032406},"volumeRatio":2.342319,"impliedVol":0.2131,"impliedVolPercentile":0.2749},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","floatShares":1250004,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.342319,"shares":1250004,"dividePrice":0,"high":104.525,"amplitude":0.005147,"preClose":104.9185,"low":103.985,"week52Low":68.046,"pbRate":"--","week52High":110.05,"institutionHeld":0,"latestPrice":104.04,"eps":0,"divideRate":0,"volume":6293,"delay":0,"ttmEps":0,"open":104.525,"prevYearClose":79.9149,"prevWeekClose":103.4597,"prevMonthClose":106.46,"prevQuarterClose":96.2686,"fiveDayClose":103.4597,"twentyDayClose":106.77,"sixtyDayClose":93.7129},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBP\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658903675","title":"百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務 不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","BIOY","PBE","BBP","APXH","WRND","LFSC","BK4588","600721","GDOC","BK0102","BK4585","GSKH","IBB","SBIO","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LFSC","PBE","BK4588","BBP","BK4585","IBB","WRND","APXH","SBIO","XLVI","BIOY","GDOC","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","IBB","LFSC","GSKH","600721","BK4588","PBE","XLVI","APXH","GDOC","BK0102","SBIO","BK0216","BBP","BIOY","WRND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962968","title":"東方證券：AI重構創新藥研發底座 國內相關產業鏈公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：技术颠覆成本，AI重构制药“快与省”是中国创新药崛起的底层逻辑，根基是人才红利和成本优势。专家与AI协同，将真正提升新药研发的成功率并缩短周期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GDOC","BK0276","03958","AGIX","SBIO","APXH","BIOY","BK0012","BBP","BK0028","VTHR","GSKH","LFSC","XLVI","BK0183","ARTY","BK0188","600958","IBB","AIPO","CHAT","BK1147","QTOC","BK4588","BK4585","PBE","WRND","BK1564"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193258586","title":"新聞稿：Ernexa Therapeutics 引入資深生物技術高管 David Polinsky 加入董事會，為臨床階段衝刺蓄力","url":"https://stock-news.laohu8.com/highlight/detail?id=1193258586","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193258586?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 21:09","pubTimestamp":1786367399,"startTime":"0","endTime":"0","summary":"此次任命正值公司关键转折点，进一步强化了其领导团队——Ernexa 正全力推进其核心项目 ERNA-101，计划于2026年第三季度提交新药临床试验申请，并在第四季度启动首项一期临床研究。马萨诸塞州剑桥市，2026年8月10日——Ernexa Therapeutics，一家致力于开发创新细胞疗法以治疗晚期癌症和自身免疫性疾病的行业先锋，今日宣布任命 David Polinsky 为其董事会成员。“我们正步入 Ernexa 历史上最为重要的时期之一，”Ernexa Therapeutics 总裁兼首席执行官 Sanjeev Luther 表示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ERNA","XBI","RFL","SYNB","IND","LENZ","BK4139","BBP","BK4205","BK4233","BK4007","BK4581","IBB","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658535936","title":"GLP-1為王、專利懸崖逼近、新賽道搶跑 跨國藥企2026上半年業績背後的版圖重組","url":"https://stock-news.laohu8.com/highlight/detail?id=2658535936","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658535936?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363243,"startTime":"0","endTime":"0","summary":"近日，全球制药巨头相继交出上半年成绩单。礼来、诺和诺德、赛诺菲、阿斯利康、辉瑞、罗氏等头部企业业绩陆续揭晓。GLP-1赛道的王座之争已无悬念，而专利悬崖、集采冲击与管线焦虑，正迫使跨国药企加速寻找下一个增长引擎。GLP-1王座之争：礼来登顶8月5日，礼来公布2026年上半年业绩——总营收427.73亿美元，同比增长49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608103836820982.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608103836820982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BBH","GSKH","JDOC","PBPH","MEDI","APXH","BK4144","BK4590","FXH","BME","TMED","IHE","BBP","FHLC","TRUH","RSPH","IYH","PPH","GLP","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641919","title":"GLP-1為王、專利懸崖逼近、新賽道搶跑：跨國藥企2026上半年業績背後的版圖重組","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641919","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641919?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:49","pubTimestamp":1786110543,"startTime":"0","endTime":"0","summary":"近日，全球制药巨头相继交出上半年成绩单。礼来、诺和诺德、赛诺菲、阿斯利康、辉瑞、罗氏等头部企业业绩陆续揭晓。GLP-1赛道的王座之争已无悬念，而专利悬崖、集采冲击与管线焦虑，正迫使跨国药企加速寻找下一个增长引擎。GLP-1王座之争：礼来登顶8月5日，礼来公布2026年上半年业绩——总营收427.73亿美元，同比增长49%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073835488463.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073835488463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["JDOC","RSPH","BBH","PJP","GSKH","BK4590","PBPH","IHE","TMED","BME","FHLC","BBP","BK4144","MEDI","TRUH","APXH","IYH","FXH","GLP","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656080539","title":"阿斯利康擬與百時美施貴寶4000億美元重組傳聞背後：專利懸崖、產品短板倒逼，AZ端反對聲大","url":"https://stock-news.laohu8.com/highlight/detail?id=2656080539","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656080539?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 17:26","pubTimestamp":1785835565,"startTime":"0","endTime":"0","summary":"蓝鲸新闻记者联系了阿斯利康方面，对方拒绝对此置评。此外，BMS有神经管线与Eliquis后续心血管资产，可补足AZ在相关领域的短板。据BMO资本在研报中指出，两家公司都没有足够的财务实力直接收购对方，预计阿斯利康能掏出约370亿美元，而百时美施贵宝约为320亿美元，远低于搞定一桩价值4000亿美元合并所需的资金。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1785835141389493693","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BBP","LU0432979614.USD","LU0321505868.SGD","LU1585245621.USD","IHE","LU1670711123.USD","PJP","LU2462157665.USD","PPH","LU1868836914.USD","LU1093756168.USD","LU1868837300.USD","LU0128525929.USD","GSKH","LU1032466523.USD","TMED","AZ","LU0225284248.USD","BMY","IE00B2B36J28.USD","JDOC","LU2242646821.SGD","TRUH","FHLC","LU2089984988.USD","AZN","LU0882574055.USD","AZNH","IYH","MEDI","LU0267386448.USD","RSPH","LU0321505439.SGD","APXH","LU0868494617.USD","FXH","LU0985481810.HKD","LU2237443895.HKD","LU2596442595.SGD","LU1868836591.USD","BK4559","PBPH","BBH","FTXH","LU2237443382.USD","LU1093756325.SGD","BK4588","LU1670710588.SGD","IE00BJJMRZ35.SGD","BME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104860953","title":"全球能源市場速覽：市場動態簡報","url":"https://stock-news.laohu8.com/highlight/detail?id=1104860953","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104860953?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 21:53","pubTimestamp":1785419602,"startTime":"0","endTime":"0","summary":"0951 ET - 美国天然气期货价格走低，市场正静待美国能源信息署于北京时间10:30发布的周度库存报告。市场普遍预期，数据将显示天然气库存增幅超出常态，从而进一步扩大相对于五年平均水平的盈余。然而，英国央行的声明称，目前几乎没有迹象表明高能源价格会引发第二轮效应，并指出工资增长正在放缓，劳动力市场疲软。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FXR","IDEV","TSLT","TSLI","ERX","VTV","TSLP","CGUS","PMDE","RJZ","FLXI","SDOG","PSC","FLGB","TSLZ","CGVV","XOEX","CRSH","AVSD","LCO","EES","TLA","AGGZ","TSLW","TEQI","EQRR","FT","DECU","ARP","TSL","RHTX","TACN","VAW","DIVZ","TESL","LGH","TEST","FITZ","KLCD","NSIV","BK4585","TSDD","ISVL","BBEU","CAOS","CLIX","BOE","KOMP","07366","09366","TSLQ","IUS","MODL","MDLV","RMIF","TCTL","LRCY","DHLX","CGDV","DFUV","VDE","VXZ","REMC","IMCG","FXD","MAPP","TSLS","RULE","BKDV","PRVS","FXL","BK4588","BAMA","TSII","BBP","SAMT","ILCV","07766","TSLL","TSLR","FLV","PLGI","TSLG","TSLO","LCG","TSLY","ANEW","ESLV","BSR","BK4582","REGL","09766","CDC","HIDV","UCC","SPCT","CGUI","VOTE","TSYY","ADPV","IJK","PEVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130972902","title":"全球外匯與固定收益市場綜述：交易動態一覽","url":"https://stock-news.laohu8.com/highlight/detail?id=1130972902","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130972902?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 23:31","pubTimestamp":1785166282,"startTime":"0","endTime":"0","summary":"Bitfinex分析指出，本周美联储会议对金融市场的影响，很可能为比特币的下一个交易阶段奠定基调。该公司表示，当比特币触及68,000至68,500美元阻力位时，价格如何反应至关重要。Bitfinex认为，周三美联储的利率决议将是决定比特币走向何方的重要催化剂。目前比特币报64,634美元，几无变动；以太坊上涨1%至1,932美元；XRP则下跌1%至1.09美元。与此同时，以太坊上涨0.5%至1,922美元，XRP下跌1.3%至1.09美元，Solana则基本持平于75.28美元附近。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EQRR","PLGI","VTV","BK4588","RGLO","VAW","DIVZ","US6M.BOND","FT","PEVC","CDIG","US2Y.BOND","US10Y.BOND","AVSD","BAMA","FXL","BINT","RULE","US5Y.BOND","US30Y.BOND","VOOV","CAOS","BITW","LRCY","HIDV","RJZ","BK4585","US7Y.BOND","TLT","OOQB","FXR","FARX","US12M.BOND","CLIX","AFIX","FITZ","CGDV","BBP","TLTW","DFUV","NGHT","US3Y.BOND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654091684","title":"總部位於荷蘭阿姆斯特丹的全球生物製藥公司 ARGENX將以每股77美元的現金收購FORTE BIOSCIENCES。","url":"https://stock-news.laohu8.com/highlight/detail?id=2654091684","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654091684?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 13:03","pubTimestamp":1785128639,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","UDN","MRNY","MRNX","UUP","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167452376","title":"全球外匯與固收市場動態：市場對話精選","url":"https://stock-news.laohu8.com/highlight/detail?id=1167452376","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167452376?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 16:16","pubTimestamp":1784794612,"startTime":"0","endTime":"0","summary":"随着中东紧张局势升级推高油价，全球市场对通胀与利率前景的担忧加剧，外汇与固定收益市场出现显著波动。英镑可能回吐近期涨幅。ING预计该汇率年底将升至0.88，2027年达到0.90。市场对英国央行在2026年加息的预期升温。数据显示，交易员目前预计2026年英国央行将累计加息38个基点。市场日益关注国债收益率的绝对水平。30年期美国国债收益率上涨0.2个基点至5.149%，接近两个月高点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRCY","ILCV","CCRV","FTRI","DECU","FLXI","DHLX","EPV","TSLS","CLIX","UCC","TSII","PLGI","FLLA","US5Y.BOND","US6M.BOND","US30Y.BOND","CRSH","ARP","TSLO","BNO","EDGH","IJK","REMC","XLE","VTV","AVSD","UCO","DCMT","GSG","TLA","US12M.BOND","BCI","KLCD","MLPX","TSLR","XLEX","OILT","EUM","CGDV","FBZ","DFUV","DBE","TSLL","VDE","MAPP","PSC","UGA","CGUI","NSIV","FXD","LCO","TEST","TLT","HFGM","CMCI","NANR","MODL","IMCG","OILU","HCOM","BCD","XES","RORO","SAMT","TSLY","RHTX","US2Y.BOND","UAE","FXL","SDOG","VOTE","RAAX","KOOL","DBO","IXC","PEVC","DRIP","TSYY","COLO","IEO","PPI","09366","EES","TCTL","UCIB","FTXN","BINT","CDIG","VOOV","TURF","PIT","HIDV","US10Y.BOND","USOI","LGH","ILF","USL","TEQI","ERX","PXE","RMIF","PDBC","OILK","FT","CERY","ADPV","DUG","TSLG","FLV","WTIU","VAW","DJP","RJZ","GUNR","USE","OIH","OTGL","BK4570","BK4588","CMDT","DIVZ","IDEV","PMDE","QPX","ACOM","CDC","09766","CGUS","DBC","PRVS","TSLT","BGH","TLTW","US3Y.BOND","BBEU","TSL","SDCI","KOMP","AGGZ","HGER","SPCT","RJI","TSLZ","SCO","TSLI","TESL","COM","ESLV","BAMA","ISVL","CMDY","EMPB","FITZ","FXR","MDLV","VXZ","XOP","DIG","TACN","BKDV","BSR","FLGR","XOEX","BK4585","GUSH","CGVV","TXUE","BBP","COMT","REGL","07366","07766","BKIV","IUS","BWET","TSLP","RGLO","USO","TSDD","TSLQ","TMF","LCG","IUSV","FLBR","ANEW","DRLL","RULE","CAOS","EQRR","NBCM","TSLW","PXJ","US7Y.BOND","AVIE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653752990","title":"安永：至2028年全球前25大醫藥企業存在千億美元增長缺口","url":"https://stock-news.laohu8.com/highlight/detail?id=2653752990","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653752990?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 19:23","pubTimestamp":1784719424,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MRNY","BBP","MRNX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653584157","title":"創新藥研發加速遇「猴荒」","url":"https://stock-news.laohu8.com/highlight/detail?id=2653584157","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653584157?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 16:21","pubTimestamp":1784708497,"startTime":"0","endTime":"0","summary":"“要站在‘猴’里，不要像猴子一样站在那里。”资本市场从来不缺故事。近期，昭衍新药业绩暴增，原因是实验猴市场价格上涨，带动公司手里的“猴子资产”大幅增值，多家相关概念公司股价也跟风大涨。甚至有人顺藤摸瓜，挖出了“香蕉概念”。网友戏称：这是产业链挖掘最深的一次。一只猴子，为什么能扰动资本市场？答案藏在药物的研发链条里。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817277458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817277458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBB","SBIO","BBP","APXH","WRND","BIOY","BK4588","XLVI","BK4585","GDOC","LFSC","GSKH","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651774435","title":"免疫疾病生物製藥公司Attovia(ATTO.US)申請在美上市 擬募資1億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651774435","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651774435?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 11:17","pubTimestamp":1784085422,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，临床阶段生物制药公司Attovia Therapeutics已提交首次公开募股申请，计划募集最多1亿美元资金。该公司计划在纳斯达克上市，股票代码为“ATTO”。　　据悉，Attovia利用其ATTOBODY平台开发用于治疗免疫介导性疾病的生物制剂。Alamar于2023年设立Attovia作为独立公司，以便自身专注于蛋白质组学和疾病检测业务，目前仍是Attovia的重要股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260715/32307966.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IBBQ","BBP","MRNX","MRNY","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651435511","title":"免疫疾病生物製藥公司Attovia(ATTO.US)申請在美上市 擬募資1億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651435511","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651435511?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 10:45","pubTimestamp":1784083531,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，临床阶段生物制药公司Attovia Therapeutics已提交首次公开募股申请，计划募集最多1亿美元资金。据悉，Attovia利用其ATTOBODY平台开发用于治疗免疫介导性疾病的生物制剂。自通过IPO融资2.2亿美元以来，Alamar股价已上涨近60%。Alamar于2023年设立Attovia作为独立公司，以便自身专注于蛋白质组学和疾病检测业务，目前仍是Attovia的重要股东。Attovia的核心候选药物ATTO-1310针对白细胞介素-31，目前已完成针对健康志愿者以及患有慢性瘙痒症和特应性皮炎患者的Ⅰ期临床试验给药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MRNX","BBP","MRNY","IBBQ","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651435505","title":"免疫疾病生物製藥公司Attovia(ATTO.US)申請在美上市 擬募資1億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651435505","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651435505?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 10:45","pubTimestamp":1784083531,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBP","MRNY","IPOS","IBBQ","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162210","title":"英硅智能早盤升逾7% 與康哲藥業達成AI+創新藥研發新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162210","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651162210?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 10:02","pubTimestamp":1783908120,"startTime":"0","endTime":"0","summary":"　　英硅智能早盘涨超7%，截至发稿，股价上涨6.21%，报45.48港元，成交额3.32亿港元。　　7月13日，据英硅智能官微消息，公司宣布与康哲药业在中枢神经系统领域开展另一项AI驱动的药物发现合作。　　根据合作协议，双方将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，双方共同推进该研发项目的合作开发。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9058117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CHAT","IE00BVYPNQ40.USD","IE00BVYPNP33.GBP","GDOC","QTOC","SG9999015986.USD","IE00BYV24P56.USD","BK1593","VTHR","WRND","SG9999004220.SGD","SG9999015952.SGD","BK1191","BK4585","AIPO","SG9999015945.SGD","PBE","SBIO","00867","GSKH","IE00BMCWC346.EUR","LU2488822045.USD","AGIX","BK4588","IE00BGHQDM52.EUR","ARTY","BBP","LFSC","SG9999015978.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649995043","title":"韓國上半年生物製藥出口額料達45億美元，創歷史同期新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2649995043","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649995043?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 13:35","pubTimestamp":1783488929,"startTime":"0","endTime":"0","summary":"根据韩国食品药品安全部的数据，该产品类别今年前六个月的出口额预计为45亿美元，同比增长15.3%，在上半年价值52亿美元的全部药品出口中占比达86.5%。韩国生物制药出口额从2023年的49亿美元增长至2025年的76亿美元。法国首次在上半年跻身韩国生物制药产品十大出口目的地之列，出口额达1.6亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2026/07/08133557738826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BBP","MRNX","MRNY","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649095087","title":"韓國上半年生物製藥出口額料達45億美元，創歷史同期新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2649095087","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649095087?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 13:20","pubTimestamp":1783488000,"startTime":"0","endTime":"0","summary":"韩国政府周三公布的数据显示，今年上半年韩国生物制药产品出口额预计将创下历史新高。　　根据韩国食品药品安全部的数据，该产品类别今年前六个月的出口额预计为45亿美元，同比增长15.3%，在上半年价值52亿美元的全部药品出口中占比达86.5%。　　韩国生物制药出口额从2023年的49亿美元增长至2025年的76亿美元。法国首次在上半年跻身韩国生物制药产品十大出口目的地之列，出口额达1.6亿美元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-08/doc-inihaieh4894099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","MRNX","MRNY","BBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":44,"code":"91000000","status":"200"}]}}